The goal of our research program is to harness a multi-omics approach to develop precision immunosuppression management strategies and identify novel therapeutic targets in advanced lung disease and lung transplantation. 

We collaborate strongly with the Thoracic Immunobiology Lab to develop and test hypotheses in mouse models of lung injury, disease and transplantation and with the Genome Technology Access Center to engage the latest sequencing and computational biology tools. 

Ongoing Projects

  • Influence of Mycophenolic Acid Pharmacogenomics on Lung Transplant Outcomes (NHLBI) 
  • The Role of DNA Damage Response Clonal Hematopoiesis in Immune Aging and Risk of CMV Activation Among Lung Transplant Recipients (Doris Duke Foundation) 
  • Influence of Genetics on Mycophenolic Acid Pharmacodynamics (Robert Wood Johnson Foundation) 
  • Role of Autophagy in Mycophenolic Acid-related Neutropenia in Advanced Lung Disease and Lung Transplantation  (WashU) 
  • Influence of Clonal Hematopoiesis on Telomere Attrition, Accelerated Immune Aging and Outcomes of Patients with Advanced Lung Disease Leading to Lung Transplantation (WashU)

Funding

NIH: National Heart, Lung and Blood Institute
Robert Wood Johnson Foundation
Institute of Clinical and Translational Sciences
Doris Duke Foundation
BJC HealthCare The Foundation